News
- Cardiovascular and Renal Drugs Advisory Committee Voted 9:3 That the Benefits of Patisiran Outweigh its Risks for the Treatment of the Cardiomyopathy of ATTR…
Kochi: India's first center of excellence for the evaluation and treatment of patients with suspected or established amyloidosis was launched today at Amrita…
Nexcella, Inc., a biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today announced…
Register for the ATTR Patient Summit April 28 - 30, 2023
HAC/TAC is proud to present the first-ever Canadian-specific ATTR Patient Summit, an…
The FDA's Center for Biologics Evaluation and Research (CBER) Office of Therapeutic Products (OTP) is hosting a public virtual workshop on Thursday, April 13, from…
Support Group Contact:
John Mathison: John@AmyloidosisSupport.org
Muriel: Muriel@AmyloidosisSupport.org
866-404-7539 (Toll-Free)
Meeting Date:
March 4, 2023…
Support Group Contact:
Kay Rowley: Kay@AmyloidosisSupport.org, 866-404-7539 (Toll-Free).
Meeting Date:
May 20, 2023
Meeting Time:
9-11am
Meeting Location Address:…
Calling all amyloidosis patients! In celebration of Amyloidosis Awareness Month, Mackenzie's Mission is creating a new FACES of Amyloidosis video. PLEASE CONSIDER…
Activity Description
Achieving health equity, eliminating disparities, and improving health for all is the ideal goal within an organization. Closing the gaps to…
Individuals suffering with rare diseases had very few therapeutic options 40 years ago. But that began to change with the stroke of a pen by then-President Ronald…